Japan’s Otsuka Sues Indian Cadila’s U.S. Unit To Block Generic
This article was originally published in PharmAsia News
Japan-based Otsuka Pharmaceutical has filed suit in a U.S. court to block a unit of Cadila Healthcare of India from making a generic version of Otsuka's Abilify (aripiprazole) for treating schizophrenia. Cadila wants to apply to the U.S. FDA for approval to market a generic, but Otsuka said its patent on the drug does not expire until 2014. The suit named Cadila's U.S. arm, Zydus Pharmaceuticals. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.